Evidence map›Paper›PMID 38432967›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer.

Yuya Yoshida, Sakura Toriyabe, Hiroo Imai, Keiju Sasaki, Yuki Kasahara, Kota Ouchi, Ken Saijo, Koichi Onodera, Chikashi Ishioka

Erratum issuedOpen access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

  • Erratum issued
    2024
5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuya YoshidaDepartment of Medical Oncology, Tohoku University Hospital, Japan.
Sakura ToriyabeDepartment of Medical Oncology, Tohoku University Hospital, Japan.
Hiroo ImaiDepartment of Medical Oncology, Tohoku University Hospital, Japan.
Keiju SasakiDepartment of Medical Oncology, Tohoku University Hospital, Japan.
Yuki KasaharaDepartment of Medical Oncology, Tohoku University Hospital, Japan.
Kota OuchiDepartment of Medical Oncology, Tohoku University Hospital, Japan.
Ken SaijoDepartment of Medical Oncology, Tohoku University Hospital, Japan.
Koichi OnoderaDepartment of Hematology, Tohoku University Hospital, Japan.
Chikashi IshiokaDepartment of Medical Oncology, Tohoku University Hospital, Japan.
Tohoku University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, immune checkpoint inhibitors (ICIs) have been used to treat several cancer types. ICIs have been reported to cause a wide variety of immune-related adverse events, including endocrine, neurologic, gastrointestinal, and cutaneous disorders. Thrombotic thrombocytopenic purpura (TTP) is an autoimmune hematologic disorder characterized by the presence of autoantibodies against a disintegrin and metalloprotease with thrombospondin-1, member 13. Several previous cases of TTP were thought to have been caused by ICI treatment. We herein report a rare case of TTP that developed after long-term treatment with an ICI (nivolumab) for gastric tube cancer.

Indexed as

NivolumabPurpura, Thrombotic ThrombocytopenicStomach NeoplasmsAgedAntineoplastic Agents, ImmunologicalFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsNivolumabgastric tube cancerhematological adverse eventsimmune checkpoint inhibitorimmunotherapy-related adverse eventsnivolumabthrombotic thrombocytopenic purpura

Identifiers

PMID38432967
PMCPMC11518592
OpenAlexW4392442962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.